Taiwan Main Orthopaedic Biotechnology (Surglasses) has received the US Food and Drug Administration 510(k) approval for its Caduceus S AR Spine Navigation System.

The Taiwanese medical device company is planning to launch its products into the US market in the first quarter of 2023.

Caduceus S is an augmented reality (AR)-powered spine navigation system, intended to be used in complex spine surgeries.

The system will reduce the number of C-arm images required to help surgeons with AR and pre-surgical planning with trajectories for spine surgery.

Surglasses said that it has designed Caduceus S to enable surgeons to superimpose the 3D spinal anatomy on a patient during surgical procedures.

Surglasses CEO and founder Wang Min Liang said: “Caduceus S is the cutting-edge technology that will enhance the spine surgical procedures accuracy and solve the complexities of the spine surgeries surgeons face during the surgery.

“Taking into consideration the small/midsize hospitals and clinics which have limited resources, Caduceus S Spine Navigation System proves to be a vital resource for the surgeons for spine surgery.

“Augmented Reality technology in Spine surgery is going to be a turning point as it significantly effects the accuracy and efficiency in doing complex surgical procedures and placing implants.”

According to the company, Caduceus S is equipped with multiple trackers that support the display of preoperatively planned trajectories through a 3D AR head-mounted display.

Its transparent head-mounted display enables the surgeons to have projections from the navigation system into the HMD, and simultaneously have a 100% field view of the patient.

Caduceus S enables the surgeons to focus on the patients, by preventing them from turning their heads to look at the external monitors in the surgical theatres, said Surglasses.

In August this year, Taiwan’s FDA (TFDA) approved Caduceus S, which is currently being used in surgical procedures in Taiwan.